Emil Kakkis is President and Chief Executive Officer of Ultragenyx Pharmaceutical Inc. (RARE). The company reported total compensation of $11,405,535 for fiscal year 2025.
| Salary | $861,100 |
|---|---|
| Bonus | $0 |
| Stock awards | $8,364,938 |
| Option awards | $1,847,356 |
| Non-equity incentive plan | $299,663 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $32,478 |
| Total | $11,405,535 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Ultragenyx Pharmaceutical Inc. filed March 27, 2026, accession 0001308179-26-000174.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $861,100 | $0 | $8,364,938 | $1,847,356 | $299,663 | $0 | $32,478 | $11,405,535 |
| FY2024 | President and Chief Executive Officer | $856,008 | — | $9,374,511 | $2,715,600 | $757,768 | — | $13,800 | $13,717,687 |
| FY2023 | President and Chief Executive Officer | $823,692 | — | $9,456,663 | $2,161,782 | $622,656 | — | $13,200 | $13,077,993 |
| FY2022 | President and Chief Executive Officer | $796,154 | $0 | $7,463,295 | $3,310,681 | $558,000 | $0 | $12,200 | $12,140,330 |
| FY2021 | President and Chief Executive Officer | $768,846 | — | $5,410,512 | $2,835,580 | $499,100 | — | $8,700 | $9,522,738 |
| FY2020 | President and Chief Executive Officer | $759,231 | $0 | $1,906,720 | $1,802,869 | $668,850 | $0 | $6,550 | $5,144,220 |
| FY2019 | President and Chief Executive Officer | $714,000 | $0 | $2,702,000 | $2,650,784 | $479,808 | $0 | $39,887 | $6,586,479 |
Totals as disclosed in each year's own compensation disclosure for Ultragenyx Pharmaceutical Inc..
| Peer-group chief executive median | $13,350,777 |
|---|---|
| Difference from that median | $-1,945,242 |
| Percentile within the disclosed peer group | 47th |
| Peers with a disclosed figure | 18 |
Medians and percentiles are computed across the peer group Ultragenyx Pharmaceutical Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Emil Kakkis this page | President and Chief Executive Officer | $11,405,535 |
| Erik Harris | Chief Commercial Officer and Executive Vice President | $4,045,072 |
| Eric Crombez | Chief Medical Officer and Executive Vice President | $4,002,173 |
| Howard Horn | Chief Financial Officer, Corporate Strategy and Executive Vice President | $3,750,607 |
| Karah Parschauer | Chief Legal Officer & Corporate Affairs, Executive Vice President | $3,509,313 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Ultragenyx Pharmaceutical Inc. compensation brief.
Emil Kakkis's compensation sits inside Ultragenyx Pharmaceutical Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Ultragenyx Pharmaceutical Inc. (RARE) compensation brief